XML 35 R24.htm IDEA: XBRL DOCUMENT

SEGMENT INFORMATION (Tables)

9 Months Ended

Jun. 30, 2024

SEGMENT INFORMATION

Schedule of information regarding operations by segment

Information regarding operations by segment for the three-month period ended June 30, 2024 is as follows:


		Therapeutic DNA			MDx Testing			DNA Tagging and
		Production			Services and Kits			Security Products			Consolidated
Revenues:
Product revenues		$	218,858		$	—		$	27,786		$	246,644
Service revenues			59,901			—			166,244			226,145
Clinical laboratory service revenues			—			325,930			—			325,930
Less intersegment revenues			—			(1,200)			—			(1,200)
Total revenues			278,759			324,730			194,030			797,519
Gross profit			194,341			(12,260)			63,151			245,232
Loss from segment operations (a)			(1,319,093)			(231,160)			(693,953)			(2,244,206)

Information regarding operations by segment for the three-month period ended June 30, 2023 is as follows:


		Therapeutic DNA			MDx Testing			DNA Tagging and
		Production			Services			Security Products			Consolidated
Revenues:
Product revenues		$	230,544		$	—		$	86,406		$	316,950
Service revenues			174,962			—			250,732			425,694
Clinical laboratory service revenues			—			2,188,817			—			2,188,817
Less intersegment revenues			—			(14,120)			—			(14,120)
Total revenues		$	405,506		$	2,174,697		$	337,138		$	2,917,341
Gross profit		$	290,541		$	829,798		$	148,979		$	1,269,318
(Loss) income from segment operations (a)		$	(717,126)		$	14,742		$	(998,966)		$	(1,701,350)

Information regarding operations by segment for the nine-month period ended June 30, 2024 is as follows:


		Therapeutic DNA			MDx Testing			DNA Tagging and
		Production			Services and Kits			Security Products			Consolidated
Revenues:
Product revenues		$	477,010		$	—		$	470,076		$	947,086
Service revenues			202,635			—			476,142			678,777
Clinical laboratory service revenues			—			1,004,250			—			1,004,250
Less intersegment revenues			—			(11,800)			—			(11,800)
Total revenues		$	679,645		$	992,450		$	946,218		$	2,618,313
Gross profit		$	462,464		$	(56,703)		$	366,219		$	771,980
Loss from segment operations (a)		$	(3,743,588)		$	(1,026,263)		$	(1,978,308)		$	(6,748,159)

Information regarding operations by segment for the nine-month period ended June 30, 2023 is as follows:


		Therapeutic DNA			MDx Testing			DNA Tagging and
		Production			Services			Security Products			Consolidated
Revenues:
Product revenues		$	560,000		$	—		$	570,800		$	1,130,800
Service revenues			434,287			—			392,526			826,813
Clinical laboratory service revenues			—			10,726,214			—			10,726,214
Less intersegment revenues			—			(96,120)			—			(96,120)
Total revenues		$	994,287		$	10,630,094		$	963,326		$	12,587,707
Gross profit		$	676,942		$	4,413,130		$	364,364		$	5,454,436
(Loss) income from segment operations (a)		$	(2,623,502)		$	1,616,914		$	(2,388,417)		$	(3,395,005)

(a)

Segment operating (loss) income consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

Schedule of reconciliation of segment loss from operations to corporate (loss) income


		June 30,
		2024			2023
Loss from operations of reportable segments		$	(2,244,206)		$	(1,701,350)
General corporate expenses (b)			(1,102,487)			(1,157,759)
Interest income			36,295			26,783
Unrealized gain (loss) on change in fair value of warrants classified as a liability			5,160,000			(278,400)
Other (expense) income, net			(101)			(3,469)
Consolidated income (loss) before provision for income taxes		$	1,849,501		$	(3,114,195)


		June 30,
		2024			2023
Loss from operations of reportable segments		$	(6,748,159)		$	(3,395,005)
General corporate expenses (b)			(4,005,351)			(3,387,464)
Interest income			84,972			34,108
Unrealized gain on change in fair value of warrants classified as a liability			9,564,000			334,700
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification			(394,000)			—
Transaction costs allocated to registered direct offering			(633,198)			—
Loss on issuance of warrants			(1,633,767)			—
Other (expense) income, net			(9,060)			6,396
Consolidated loss before provision for income taxes		$	(3,774,563)		$	(6,407,265)

(b)

General corporate expenses consist of selling, general and administrative expenses that are not specifically identifiable to a segment.